Diffuse large B-cell lymphomas (DLBCLs) are aggressive B-cell lymphomas that are clinically, pathologically, and genetically diverse, in part reflecting the functional diversity of the B-cell system. The focus in recent years has been toward incorporation of clinical features, morphology, immunohistochemistry, and ever evolving genetic data into the classification scheme. The 2008 World Health Organization classification reflects this complexity with the addition of several new entities and variants. The discovery of distinct subtypes by gene expression profiling heralded a new era with a focus on pathways of transformation as well as a promise of more targeted therapies, directed at specific pathways. Some DLBCLs exhibit unique clinical characteristics with a predilection for specific anatomic sites; the anatomic site often reflects underlying biological distinctions. Recently, the spectrum of Epstein-Barr virus (EBV)Ydriven B-cell proliferations in patients without iatrogenic or congenital immunosuppression has been better characterized; most of these occur in patients of advanced age and include Epstein-Barr virus (EBV)Ypositive large B-cell lymphoma of the elderly. Human herpesvirus 8 is involved in the pathogenesis of primary effusion lymphoma, which can present as a ''solid variant.'' Two borderline categories were created; one deals with tumors at the interface between classic Hodgkin lymphoma and DLBCL. The second confronts the interface between Burkitt lymphoma and DLBCL, so-called ''B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma'' in the 2008 classification. Most cases harbor both MYC and BCL2 translocations and are highly aggressive. Another interesting entity is anaplastic lymphoma kinaseYpositive DLBCL, which renders itself potentially targetable by anaplastic lymphoma kinase inhibitors. Ongoing investigations at the genomic level, with both exome and wholegenome sequencing, are sure to reveal new pathways of transformation in the future.
D iffuse large B-cell lymphomas (DLBCLs) are aggressive lymphomas with tremendous heterogeneity in terms of clinicopathologic and molecular genetic features. From a morphologic standpoint, the current 2008 World Health Organization (WHO) classification defines DLBCL as a diffuse growth of neoplastic large B lymphoid cells with a nuclear size equal to or exceeding normal macrophage nuclei. 1 Diffuse large B-cell lymphoma is the most common lymphoma subtype and accounts for 30% to 40% of adult non-Hodgkin lymphoma (NHL). The diversity of the DLBCL group is being slowly unraveled, and the 2008 WHO classification lists a large number of DLBCL subgroups primarily based on distinct morphologic, biologic, immunophenotypic, or clinical parameters. 1 A significant proportion of DLBCLs remains biologically heterogeneous and does not fit into any specific disease subgroups; these are defined as DLBCL, not otherwise specified (DLBCL-NOS). Although substantial progress has been made toward molecular subclassification of this entity, the translation to effective treatment strategies remains a challenge.
Historically, lymphoma classification has been based on the presumed normal counterpart. Thus, some of the subtypes of DLBCLs reflect the putative cell of origin, for example, mature B-cell versus more differentiated plasma cells. However, adopting this methodology as the sole means of classification is perhaps inadequate or incomplete in defining certain subtypes of lymphoma, for example, intravascular large B-cell lymphoma. In addition, the focus has shifted toward pathogenetic pathways that might be the subject of molecularly targeted therapy. As such, a number of aggressive B-cell lymphomas are defined primarily on the basis of either specific genetic aberrations, such as anaplastic lymphoma kinase (ALK)Ypositive large B-cell lymphoma, or viruses involved in B-cell transformation, for example, primary effusion lymphoma (PEL). This review emphasizes some of the implications of gene expression studies in DLBCL-NOS, entities that have been recognized more recently, as well as areas of diagnostic challenge, such as the interface between DLBCL and Burkitt lymphoma (BL).
DLBCL, Not Otherwise Specified
Diffuse large b-cell lymphoma, not otherwise specified, is the most common type of lymphoma on a worldwide basis, accounting for 25% to 30% of NHLs. Although most cases of DLBCL-NOS are de novo, this diagnosis also includes histologically transformed low-grade B-cell malignancy, such as follicular lymphoma or chronic lymphocytic leukemia, so-called Richter's transformation. Diffuse large B-cell lymphoma, not otherwise specified, is more common in the elderly but occurs in all age groups. Males are more commonly affected, and sites of involvement include lymph nodes or extranodal sites (bone, skin, thyroid, gastrointestinal tract, and lung). The most common genetic aberrations in DLBCL-NOS involve the BCL6 gene, seen in 30% of cases. 2 Translocation involving MYC (up to 10% of cases) 3, 4 and BCL2 5 is frequent in lymphomas of the germinal center B-cell subgroup (see below).
Diffuse large B-cell lymphoma, not otherwise specified, is a diagnosis of exclusion, not corresponding to one of the specific subtype described below. The focus in recent years has been toward identification of molecular alterations and specific pathways leading to transformation. 6Y8 Gene expression profiling (GEP) of DLBCLs has identified molecular subtypes, which correlate with prognosis, and may have relevance for treatment based on signaling pathways. Studies by the Staudt laboratory have shown that at least 2 major types of DLBCL could be identified by GEP, resembling either germinal center B cells (GCBs) or activated B cells (ABCs), establishing a putative ''cell of origin.'' 9Y11 The original GEP studies by Alizadeh et al 10 used samples from patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and related regimens before the rituximab era and demonstrated a significantly worse prognosis for the ABC subtype, independent of other clinical factors. Although the introduction of rituximab to traditional CHOP therapy has improved outcomes in the ABC subtype, this subtype still remains less responsive to therapy than the GCB subtype. 12 Prognostic models based on limited sets of genes have been proposed. 13 Other studies used GEP to examine aspects of cell metabolism or tumor microenvironment. 14 Immune escape of the tumor cells from T-cell surveillance was the subject of still other studies. 15Y17 A detailed review is beyond the scope of this article.
The ABC and GCB DLBCL subtypes, originally formulated based on a cell-of-origin model, have more recently been shown to harbor different pathways of cellular transformation and oncogenesis. 18, 19 Regarding the ABC subtype, the major signaling alteration appears to be the constitutive activation of the nuclear factor JB (NF-JB) pathway through chronic stimulation of the B-cell receptor (BCR) pathway. Ngo et al. have demonstrated the role of the CBM complex, CARD11, BCL10, and MAL1, downstream of BCR in NF-JB activation. 20 Mutations in CARD11 are observed in approximately 10% of ABC DLBCLs. A majority of other ABC DLBCLs have been shown to have chronic activation of the BCR pathway through various other mechanisms including activating mutations of CD79A and CD79B and recruitment of Bruton's tyrosine kinase, which is required for CARD11 signaling. 6 At present, GEP data do not dictate therapy by current standards of care. However, recent data have shown the efficacy of bortezomib, a proteasome inhibitor that blocks NF-JB signaling, in improving response rate and median survival for the ABC subtype of DLBCL but predictably not for the GCB subtype in the relapsed setting. 21 Several studies have also addressed the potential of BCR pathway down-regulation by blocking various downstream signaling molecules including Btk, phosphatidylinositol 3 kinases, spleen tyrosine kinase, mammalian target of rapamycin, and SRC family kinases. 22 The efficacy of small-molecule inhibitors against several of these targets has been described via either in vitro experiments or clinical trials.
Because of the technical difficulties in performing GEP on every case, various immunohistochemical profiles have been proposed as surrogates of the GEP. Although the correspondence is not exact, similar prognostic correlations can be drawn with immunohistochemically defined groups. 23Y25 Several genes characteristic of germinal center derivation have been demonstrated to be more highly expressed in the GCB subtype, for example, BCL6, CD10, LMO2, BCL7A, and so on. 10 The classic Hans algorithm utilized protein expression of BCL6, CD10, and MUM-1/IRF4, but the panel has been expanded in newer iterations known as ''Choi'' and ''Tally'' algorithms, with greater predictability of outcome ( Fig. 1 ). 25, 26 However, the concordance rate between the immunohistochemically defined subtype, ABC versus GCB, and GEP has been variable. 25, 27 A recent study showed the continued relevance of the GEP in a clinical trial utilizing rituximab plus chemotherapy, but none of the immunohistochemical algorithms used could reproduce this result. 28 As highlighted by several studies examining reproducibility among different laboratories, this lack of concordance may be in part due to variability in performing and scoring the immunohistochemical studies. 29, 30 The other consistent issue is the existence of a small percentage of ''unclassifiable cases'' by immunohistochemistry. Recently, a report from the International DLBCL Rituximab-CHOP consortium introduced a new algorithm ''Visco-Young'' based on expression of CD10, FOXP1, and BCL6, which demonstrated a 92.6% concordance with GEP and ability to independently predict progression-free and overall survival (Fig. 1C ). 31 One might question if morphologic features still have relevance for the subclassification of DLBCL, such as the recognition of centroblastic, immunoblastic, and anaplastic subtypes ( Fig. 2) . Historical studies suggested that tumors composed predominantly of centroblasts had a better prognosis than those composed of immunoblasts. 32 This is likely due to a partial correlation with GEP as the immunoblastic subtype is enriched for cases with an ABC profile, whereas purely centroblastic neoplasms are more often GCB. 9 However, reproducibility has been less than satisfactory when applied to a broad spectrum of tumors, probably reflecting interobserver variability and different criteria for designating lymphomas as the ''immunoblastic'' subtype. The use of cytological criteria was recently resurrected by Ott et al, 33 who found that immunoblastic morphology was highly significant in predicting an adverse outcome. However, in a trial of 949 patients, only 7.4% of the cases were classified as immunoblastic, which is significantly less than what would be expected for the ABC subtype based on GEP. Although authors were able to apply very stringent criteria to identify a prognostically relevant subset, because of the rarity of these lesions the utility of this approach in general practice is limited.
DLBCL Subtypes in Specific Sites
Several variants or subtypes of DLBCL have been segregated out in the WHO classification because of a propensity to affect distinct sites. These include primary DLBCL of the central nervous system (CNS), primary cutaneous DLBCL, leg type, and intravascular large B-cell lymphoma.
Primary CNS DLBCLs include those cases presenting with intracerebral or intraocular disease. The majority of patients with intraocular lesions develop contralateral tumors and cerebral lesions. The median age at presentation is 60 years, and there appears to be a male preponderance. Gene expression profiling studies have demonstrated some unique features in primary CNS tumors. 34Y36 However, a consistent pattern as ABC or GCB has not emerged. It is interesting that there appears to be a link between primary CNS DLBCL and DLBCL presenting in the testis, perhaps because both are immune privileged sites and tend to show decreased or absent expression of HLA classes I and II proteins, allowing further dodging of the immune system. 37, 38 Novel chemotherapy protocols including high-dose methotrexate have remarkably improved the previously poor prognosis. 39, 40 Primary cutaneous DLBCL, leg-type, is clinically more aggressive than other cutaneous B-cell lymphomas composed of large B cells. 41 By GEP and immunophenotype, it resembles the activated B-cell type of nodal DLBCL. 42 As with nodal DLBCL, strong BCL-2 expression is an adverse prognostic factor and correlates with the ABC GEP. 43 Primary cutaneous follicle center lymphomas may be composed predominantly of large B cells in some cases, but nevertheless have an indolent clinical course and generally do not require chemotherapy for clinical management unlike DLBCL, leg type.
Intravascular large B-cell lymphoma is a rare form of DLBCL characterized by the presence of large B cells only in the lumens of small vessels, particularly capillaries of various organs; lymph node involvement is rare. 44, 45 There are 2 distinct patterns of clinical presentation, a Western form with neurological and cutaneous manifestations and an Asian form with pancytopenia, hepatosplenomegaly, multiorgan failure, and hemophagocytic syndrome. 39, 46 The disease is often not diagnosed until autopsy, because of the lack of definitive radiological or clinical evidence of disease and diverse symptoms. Patients presenting with cutaneous disease appear to have a somewhat better prognosis, probably because of early detection. Using immunophenotyping as a surrogate for the GEP, the majority of intravascular DLBCLs have an ABC phenotype 46 and generally also express CD5.
T-Cell/HistiocyteYRich Large B-Cell Lymphoma
T-cell/histiocyteYrich large B-cell lymphoma (T/HRLBCL) is a morphologic variant of DLBCL, but one with many distinctive clinical features. 47, 48 T-cell/histiocyteYrich large B-cell lymphoma tends to present in a relatively younger age group with a median age in the fourth decade and demonstrates male predominance. It has an aggressive clinical course and often presents with advanced stage and spleen, liver, and bone marrow (one third of cases) involvement. 47Y49 Recent studies have focused on the mechanisms of recruitment of inflammatory cells and the relationship to the microenvironment. 50 Some cases appear related to nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), with the neoplastic cells being epithelial membrane antigenYpositive and resembling lymphocyte predominant cells. 51 In addition, NLPHL may progress to a process indistinguishable from de novo T/HRLBCL. The relationship of primary and secondary T/HRLBCL is not fully resolved, and in some instances, the distinction between NLPHL and T/HRLBCL can be problematic in primary biopsy specimens. Also, the diagnosis of T/HRLBCL is best rendered on excision biopsies. Needle core biopsies should be avoided for primary diagnosis and classification for this and other lymphoma subtypes.
There are several key histological features that help distinguish T/HRLBCL from NLPHL: (1) absence of small B cells, (2) lack of a follicular structure as demonstrated by absence of follicular dendritic cells, and (3) absence of T-cell rosettes around atypical B cells despite a rich T-cell background. In addition, unlike NLPHL, T/HRLBCL very rarely presents with localized stage I disease. Other cases with an overlapping morphologic appearance may be composed of Epstein-Barr virus (EBV)Ypositive cells resembling Hodgkin/Reed-SternbergYlike cells in a background rich in T cells. 52 Once considered a subtype of T/HRLBCL, EBV-positive cases are now included with in EBV-positive large B-cell lymphoma. Patients with T/HRLBCL are generally treated similarly to their DLBCL-NOS counterparts with anthracycline-containing chemotherapy, prednisone and rituximab. 49 Interestingly, T/HRLBCL is rare in pediatric patients, but when it does occur, it is most often a progression of NLPHL. 53 
EBV-Positive DLBCL
This entity is included as a provisional category in the WHO classification as EBV-positive DLBCL of the elderly. Oyama et al 54 first noted that EBV-positive B-cell lymphoproliferative disorders were more likely to occur at an advanced age and had a clinically aggressive course. Currently, it is defined as a histologically malignant polymorphic or monomorphic EBV-positive B-cell lymphoproliferation in patients who are generally older than 50 years without any known immunodeficiency, transplantation, or prior lymphoma. These patients have frequent extranodal presentation (e.g., stomach, lung, tonsils, and skin) and overall poor prognosis. Some cases show morphologic overlap with classic Hodgkin lymphoma (cHL), also encountered in the elderly, but said to have a better prognosis. 55 The lesion is thought to be related to defective immune surveillance of EBV secondary to immunosenescence, the natural decay of the immune system as a consequence of aging. 54 Dojcinov et al 56 report a large series of patients from the Western world with overall similar clinical and pathological features: median age at presentation of 75 years and an aggressive clinical course. However, identical lesions can also be seen more rarely in younger patients, sometimes occurring close to the time of primary EBV infection. 57 Dojcinov et al 56, 58 also described EBV-driven proliferations presenting in cutaneous or mucosal sites, termed mucocutaneous ulcer, which are histologically alarming, but have a much more indolent and often self-limited clinical course. The cells in mucocutaneous ulcer often have an immunophenotype resembling cHL, with expression of CD30, CD15, and variable CD20. The differential diagnoses include various EBV-related benign lymphoproliferations, EBV reactivation in an older age group, and other lymphomas such as lymphomatoid granulomatosis, plasmablastic lymphoma (PBL), and Hodgkin lymphoma. In some cases, distinction from Hodgkin lymphoma may be particularly problematic. Historically, cells resembling Reed-Sternberg cells have been described in many EBV-associated conditions ranging from infectious mononucleosis 59 to methotrexate-associated lymphoproliferative disease. 60 The correct diagnosis requires integration of clinical and pathological features, with correct interpretation of the immunophenotype in the clinical and pathological context.
Another distinctive form of EBV-positive DLBCL is DLBCL associated with chronic inflammation. This lesion was first recognized in patients with long-standing chronic pyothorax. 61 However, an identical process may be seen in areas of chronic inflammation affecting body cavities or restricted spaces, such as joints. 62 This subtype manifests in the median age group of 65 to 70 years with a striking male predominance. The typical sites of involvement include pleural cavity, bone (especially femur), joints, and periarticular soft tissue. In general, the tumor cells exhibit type III EBV latency with positive EBER (EBVencoded RNA) and LMP1 expression. They exhibit aggressive clinical behavior, and 5-year survival ranges from 20% to 35%. 63, 64 
Mediastinal (Thymic) Primary Large B-Cell Lymphoma
Primary large B-cell lymphoma (PMBL) has been recognized for a number of years as a distinct entity, based on its unique clinical and molecular features, 65, 66, 67, 68 although cytologically, it resembles many other DLBCLs. It occurs most commonly in female adolescents and young adults (median age at presentation in the fourth decade), but can also affect the pediatric age group. 69 It presents most often as early-stage, bulky disease in the mediastinum with local extension to the lung, chest wall, pleura, and pericardium with pleural and pericardial effusions. Distant extranodal disease at presentation is uncommon; however, relapse most often occurs in extranodal sites including kidneys, adrenals, liver, and CNS. Bone marrow involvement is rare. The tumor is thought to be derived from medullary B cells within the thymus gland. The cells express CD20, CD79a, OCT-2, and BOB-1 but do not express surface immunoglobulin or CD10. CD23 is often positive. Pivotal studies showed a GEP differing from other DLBCLs and resembling cHL, with up-regulation of the NF-JB pathway. 70, 71 TRAF-1 and c-REL expression was also observed, reflecting activation of NF-JB pathway. 72 Although there are many similarities between cHL and PMBL including young age of onset, presence of mediastinal mass, lack of surface immunoglobulin, and shared pathways of activation, generally, histological and immunophenotypic distinction is possible. However, CD30 is often positive (albeit weak and heterogeneous), and in some cases, the distinction from nodular sclerosis cHL can be difficult, so-called ''gray zone lymphomas'' (GZLs). 73 Regarding prognosis, a PMBL molecular signature was shown to be associated with better survival as compared with ABC and GCB DLBCL. 70 Traditional studies have suggested a need for radiation therapy in addition to CHOP-based chemotherapy for sustained complete remission in PMBL. The application of more intensive regimens, such as dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R), with the addition of rituximab appears to obviate the need for radiation, reducing long-term complications. 74Y76
DLBCLs With Plasma Cell Immunophenotype
Several types of DLBCL exhibit a plasmablastic phenotype, that is, acquisition of plasma cell markers such as CD38/ CD138 with loss of or weak B-cell markers and MUM-1 positivity. These include ALK-positive large B-cell lymphoma, PBL, and PEL.
Anaplastic lymphoma kinaseYpositive large B-cell lymphoma is a rare subtype (G1% of DLBCL) in which the neoplastic cells resemble transformed cells with a terminally differentiated B-cell/plasma cell phenotype. 77 It occurs in all age groups (9Y70 years) with a male predominance and mainly involves lymph nodes sometimes with mediastinal involvement. 78, 79 Several translocations leading to growth factorYindependent activation of ALK have been demonstrated; the t(2;17) involving ALK and clathrin is the most common of these, but the classic t(2;5) of anaplastic large cell lymphoma can also be seen. Recently, cytogenetically complex SEC31A-ALK fusion was shown to be recurrent. 80 Most cases express cytoplasmic IgA, and there is often a down-regulation of mature B cellYassociated antigens such as CD20 and PAX-5. In contrast to ALK-positive anaplastic large cell lymphoma, CD30 is negative, CD138 is positive, and prognosis is dismal with poor response to conventional CHOP-based chemotherapy. 81 Small-molecule inhibitors of ALK carry a promising future, especially with the recent approval of crizotinib (Xalkori capsules; Pfizer, Inc., New York, NY), the small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases for treatment of nonYsmall cell lung carcinoma. 82 There is at least 1 clinical trial assessing the use of crizotinib in ALK-positive tumors in a nonYlung cancer context (NCT01121588).
Plasmablastic lymphoma was initially described in the oral cavity in the setting of HIV infection. 83 However, PBL can occur in other settings of decreased immune surveillance, such as advanced age and congenital or acquired iatrogenic immunosuppression. 84 The median age at presentation is 50 years with a male predominance; most patients are at an advanced stage (stage III or IV). The majority of cases are EBV-positive with a latency I phenotype. They typically present in extranodal sites, often with a mucosal or cutaneous localization. The morphology of neoplastic cells ranges from plasmablastic to immunoblastic. Some cases demonstrate more mature-appearing plasma cells, and the immunophenotypic profile overlaps with that of plasma cell myeloma. 84, 85 Recent studies have shown a high incidence of MYC translocations in PBL, 86, 87 and similar genetic anomalies in plasma cell myeloma undergoing blastic transformation provide evidence for a link between myeloma and PBL. 88 Plasmablastic lymphoma demonstrates an early response to therapy albeit with high relapse rates and overall poor prognosis. 89 Recent studies show that prognosis remains poor in HIV-positive patients despite highly active antiretroviral therapy. 90 Primary effusion lymphoma is a lymphoproliferative disorder associated with human herpesvirus 8 (HHV-8) infection. 91 It occurs most commonly in young or middle-aged males with HIV infection. Usually, there is coinfection with EBV. In the absence of HIV infection, it is seen predominantly in the elderly, especially in individuals of Mediterranean origin, which has high HHV-8 infection prevalence. 92 Some affected patients also have a history of Kaposi sarcoma and less commonly multicentric Castleman disease (MCD). 93 The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Some cases may present with tumor masses involving the gastrointestinal tract, soft tissue, and other extranodal sites, termed extracavitary PEL. 94 The morphology of the tumor cells varies from plasmablastic, immunoblastic, to frankly anaplastic. The differential diagnosis includes pyothorax-associated DLBCL, which presents with a pleura-based lesion and is usually EBV-positive, but HHV-8Ynegative. Both tumor types can have aberrant cytoplasmic CD3 expression, which is a diagnostic pitfall as B-cell markers can be lost. 95, 96 Immunohistochemistry for the HHV-8/Kaposi sarcoma-associated herpes virus-associated associated latent protein (LANA) is positive. Generally, EBER in situ hybridization is positive, and LMP-1 is negative. Interestingly, stabilization of MYC also has been implicated in the pathogenesis of PEL through unknown mechanisms. 97, 98 The prognosis is extremely poor with a median survival reported to be less than 6 months.
A related disorder is large B-cell lymphoma arising in HHV-8Yassociated MCD. 99 The patient group is similar to that described for PEL with HIV infection, frequent Kaposi sarcoma, and enlarged lymph nodes and spleen. Activation of the IL-6 signaling pathway mediates many of the clinical stigmata in MCD and in these patients. 100 This process represents an expansion of plasmablastic cells within a lymph node in the setting of MCD. The cells express immunoglobulin M lambda, but monoclonality has been absent at the genetic level. Generally, EBV coinfection is not observed; however, variations on this theme with unusual lymphoid proliferations coinfected with both EBV and HHV-8 have been described more recently. 101 
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma
This category was introduced in the 2008 WHO classification to address cases that have features intermediate between DLBCL and BL in terms of morphology, immunophenotype, or cytogenetics and generally behave clinically in a more aggressive fashion. 102 This is a relatively rare entity that is seen mostly in adults with widespread nodal and extranodal disease along with leukemic manifestations in some patients. The distinction of BL from morphologically similar aggressive B-cell lymphomas has been problematic for pathologists and clinicians. For years, a variety of terms have been used to describe lymphomas with morphologic features resembling BL, but of uncertain biological linkage: small noncleaved, non-Burkitt, atypical BL, Burkitt-like lymphoma. The use of these terminologies is discouraged in the context of the current WHO 2008 lymphoma lexicon (Fig. 3) .
Gene expression profiling studies have shed some light on the spectrum of aggressive B-cell lymphomas bordering on BL. Burkitt lymphoma has a characteristic GEP, but there are cases morphologically within the spectrum of DLBCL with a similar GEP. 104, 105 Some harbor MYC translocations as a sole abnormality (MYC simple karyotype), whereas others have more complex abnormalities in association with MYC translocation (MYC complex karyotype). Sometimes, MYC translocations are detected along with either BCL2 (more frequent) or BCL6 translocations, so called ''double-hit lymphomas.'' Rarely, translocations involving MYC, BCL2, and BCL6 are seen together, hence the terminology ''triple-hit lymphomas.'' Double-hit lymphomas are generally refractory to standard chemotherapy regimens and have a poor prognosis. 106Y108 The poor prognosis of this subgroup is most likely due to the additive effect of having MYC and BCL2 dysregulation, leading to simultaneous increased proliferation and decreased apoptosis, respectively, in combination with the genomic complexity seen in these patients. 102 A recent study has suggested that high expression of MYC and BCL-2 proteins carries the same prognostic significance, even if genetic studies are negative for translocation. 109 These double-hit and triple-hit lymphomas comprise the largest cohort within the category of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (B-UNC/BL/DLBCL). Other scenarios that might qualify for an entry into this diagnostic entity include (1) cases with morphologic features intermediate between DLBCL and BL, with a proliferation index approaching 100%, starry-sky appearance, and immunophenotype typical of BL; or (2) a morphologically typical BL with an aberrant immunophenotype (especially strong to moderate BCL-2 expression or Ki-67 proliferative index G95%).
Importantly, the absence of MYC translocation in an otherwise typical BL (morphologically and immunophenotypically) does not exclude the diagnosis of BL. Up to 10% of otherwise typical BLs have been shown to be negative for MYC translocation by fluorescence in situ hybridization. 39, 105, 110 Although technical issues for fluorescence in situ hybridization assays might be a consideration in some cases, other pathways leading to MYC activation (e.g., miRNA deregulation) 111 have been demonstrated. Immunohistochemistry for MYC protein may prove to be informative in these cases. Conversely, the mere presence of MYC translocation or high proliferation index (100%) by itself in an otherwise typical DLBCL would also not qualify for an entry into this category. The clinical significance of a MYC translocation in DLBCL is not yet resolved and may in part depend on the nature of the therapy used. Recent studies have suggested that MYC-positive DLBCLs treated with rituximab-CHOP have a poor prognosis, 4,112 but in preliminary data, an adverse effect was not observed in patients treated with DA-EPOCH-R at the National Cancer Institute. 3 In addition, many of the MYC-positive DLBCL in the published series did not have MYC as a sole genetic abnormality.
Certain problem areas still remain in terms of classification. One example is DLBCL with a very high proliferation rate approaching 100% and an immunophenotype typical for BL: CD20 + , CD10 + , BCL-6 + , and BCL-2 j , but lacking a demonstrable MYC translocation. At present, our view is to retain these cases within DLBCL and not B-UNC/BL/DLBCL. However, as discussed above, possibility of MYC deregulation might still be pursued via immunohistochemistry. Another ambiguous subset is composed of cases that otherwise would be classified as BL, but exhibit minor morphologic variability or weak BCL-2 expression. In the presence of a classic cytogenetic profile (i.e., isolated MYC translocation), such cases can be retained as BL and previously were referred to as atypical BL in the third edition of the WHO classification. 113 In this setting, cytogenetic studies for BCL2 should be performed to rule out an associated BCL2 translocation.
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Hodgkin Lymphoma
This category of large B-cell lymphomas (also referred to as GZL) is reserved for those cases that demonstrate clinical, morphologic, and immunophenotypic overlap between cHL and DLBCL, especially the PMBL type. These demonstrate propensity for mediastinal involvement in young male adults unlike cHL and PMBL, which occur more commonly in young females. 114 This category is felt to overlap with what had been termed Hodgkin-like anaplastic large cell lymphoma in the older literature. 115 Gray zone lymphomas are composed of large pleomorphic tumor cells that sheet out, often in a diffusely fibrotic stroma. The majority of the pleomorphic cells resemble Hodgkin cells, whereas in some areas, they are more reminiscent of PMBL. A characteristic feature is the broad spectrum of cytologic appearance. The inflammatory infiltrate is usually sparse, but scattered eosinophils, lymphocytes, and histiocytes may be present. The immunophenotypic features of GZL are also intermediate, with frequent asynchrony between the morphology and immunophenotype. 73 These include cases that resemble PMBL morphologically but demonstrate CD15 positivity or loss of CD20. On the other hand, cases that cytologically appear closer to cHL might express strong CD20 expression with retention of B-cell program in addition to CD30 and CD15 positivity. Although a close relationship between cHL and PMBL has been demonstrated via GEP, gene profiling studies of GZLs have not yet been undertaken. A recent large-scale methylation analysis demonstrated a close epigenetic relationship between GZL, cHL, and PMBL, but quite different from that of DLBCL. In addition, principal component analysis indicated that GZL did not cluster with either cHL or PMBL, but demonstrated a unique epigenetic signature. 116 The optimal treatment of GZL is not established. Despite the many similarities between cHL, PMBL, and GZL including cytogenetic aberrations, 75, 114, 115 GZL is considerably more aggressive, and patients have had a relatively poor outcome with both cHL and NHL regimens. 86, 89, 90 Prospective studies from the National Cancer Institute have shown that GZL patients with clinical features similar to the PMBL cohort treated with DA-EPOCH-R had significantly inferior event-free survival and often required consolidation mediastinal radiation. 75 Currently, for CD20-positive GZL, immunochemotherapy with rituximab, followed by radiation treatment if there is persistent positron emission tomography positive disease, is the preferred approach. 75 
CONCLUSIONS
The heterogeneity of the DLBCLs reflects the heterogeneity of B-cell neoplasms in general, and this complexity had led to an expanding number of entities in the WHO classification. Gene expression profiling has delineated at least 2 major subsets, based on a cell-of-origin model, GCB and ABC. Newer technologies and platforms may make such testing routinely available in the clinical practice setting. 110, 111 Along the same lines, better markers and improved algorithms for immunohistochemistry as a surrogate for GEP may improve categorization short of GEP based on RNA expression data.
The use of high-throughput genomic techniques will continue to add complexity to this picture. Although several criteria including clinical manifestation, morphology, immunophenotype, and certain cytogenetic features determine the final subtype, the treatment of DLBCL has not varied in recent years, with rituximab-CHOP being the standard in many clinical practices. The addition of rituximab to CHOP improved survival for most patients, but outcome was still inferior for the ABC subset in comparison with GCB. Recent data suggest that DA-EPOCH-R provides durable remissions in DLBCL and is effective in both germinal center and nongerminal center B-cell subtypes. 117 Further studies are needed to determine the optimal treatment approach for other high-risk categories, such as B-UNC/BL/DLBCL, with complex karyotypes. High-throughput genomic studies have paved the way for better understanding of DLBCLs and have led to new drug development. For example, the identification of mutations affecting B-cell signaling
